Gulf International Bank UK Ltd Sells 769 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Gulf International Bank UK Ltd cut its position in Royalty Pharma plc (NASDAQ:RPRX) by 2.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 29,757 shares of the biopharmaceutical company’s stock after selling 769 shares during the quarter. Gulf International Bank UK Ltd’s holdings in Royalty Pharma were worth $759,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the company. Franklin Resources Inc. grew its position in shares of Royalty Pharma by 5.0% in the third quarter. Franklin Resources Inc. now owns 1,460,515 shares of the biopharmaceutical company’s stock valued at $40,705,000 after purchasing an additional 70,130 shares during the last quarter. Van ECK Associates Corp grew its holdings in Royalty Pharma by 171.1% in the 3rd quarter. Van ECK Associates Corp now owns 101,500 shares of the biopharmaceutical company’s stock valued at $2,777,000 after buying an additional 64,057 shares during the last quarter. Summit Global Investments acquired a new position in shares of Royalty Pharma during the third quarter worth approximately $735,000. Pallas Capital Advisors LLC bought a new stake in shares of Royalty Pharma in the fourth quarter valued at approximately $2,355,000. Finally, Two Sigma Advisers LP boosted its position in shares of Royalty Pharma by 44.7% in the third quarter. Two Sigma Advisers LP now owns 3,033,200 shares of the biopharmaceutical company’s stock valued at $85,809,000 after acquiring an additional 936,900 shares during the period. Institutional investors own 54.35% of the company’s stock.

Royalty Pharma Price Performance

NASDAQ:RPRX opened at $33.64 on Monday. The company has a market capitalization of $19.39 billion, a price-to-earnings ratio of 23.20, a PEG ratio of 2.31 and a beta of 0.49. The company has a 50-day moving average of $30.06 and a 200-day moving average of $28.19. Royalty Pharma plc has a 52 week low of $24.05 and a 52 week high of $34.20. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. As a group, equities research analysts anticipate that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 21st will be paid a dividend of $0.22 per share. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.21. This represents a $0.88 annualized dividend and a yield of 2.62%. The ex-dividend date of this dividend is Friday, February 21st. Royalty Pharma’s dividend payout ratio is currently 60.69%.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on RPRX shares. StockNews.com upgraded shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research note on Tuesday, November 5th. TD Cowen upgraded shares of Royalty Pharma to a “strong-buy” rating in a research note on Tuesday, December 24th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Royalty Pharma presently has a consensus rating of “Buy” and a consensus target price of $41.60.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.